Effect of FTO and IGF2BP2 gene polymorphisms on duration of pregnancy and Apgar scores in women with gestational diabetes.
Gestational diabetes mellitus (GDM) is a metabolic disorder occurring in pregnant women. The main risk factors include advanced age and obesity. FTO and IGF2BP2 are the genetic loci associated with an increased risk of diabetes type 2 as well as being involved in lipid and carbohydrate metabolism. The aim of this study was to examine the association of FTO rs8050136, IGF2BP2 rs4402960 and rs11705701 gene polymorphisms with GDM risk as well as with clinical parameters of women with GDM and their newborns. This study included 204 pregnant women with GDM and 207 pregnant women with normal glucose tolerance. The diagnosis of GDM was based on a 75 g oral glucose tolerance test administered at 24-28 weeks of gestation. There were no statistically significant differences in the distribution of the FTO rs8050136 and IGF2BP2 rs4402960 and rs11705701 genotypes between women with GDM and normoglycemic women. In the women with the IGF2BP2 rs4402960 TT and rs11705701 AA genotypes, we observed a longer gestation and higher Apgar scores than in the women with other genotypes. The results of this study suggest that FTO rs8050136 and IGF2BP2 rs4402960 and rs11705701 gene polymorphisms are not associated with the risk of GDM in our population, whereas IGF2BP2 rs4402960 and rs11705701 genotype status may affect the length of gestation and the Apgar scores of newborns. IMPACT STATEMENT What is already known on this subject? Gestational diabetes mellitus (GDM) is the glucose intolerance detected during pregnancy. The main risk factors include an advanced age and obesity. FTO and IGF2BP2 are the genetic loci associated with an increased risk of diabetes type 2, as well as being involved in lipid and carbohydrate metabolism. What do the results of this study add? In this study, we examined the association between FTO and IGF2BP2 gene polymorphisms and GDM. There were no statistically significant differences in the distribution of these genotypes between healthy women and women with GDM. However, we observed a longer duration of pregnancy and higher Apgar scores in women with IGF2BP2 rs4402960 TT and rs11705701 AA genotypes. What are the implications of these findings for clinical practice and/or further research? Although the FTO rs8050136 and IGF2BP2 rs4402960 and rs11705701 gene polymorphisms are not associated with the risk of GDM in our population, further studies of these genes may allow for better neonatal care and prediction of wellbeing of newborns.